Chrysalis Bio Therapeutics just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Chrysalis Bio Therapeutics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Chrysalis BioTherapeutics, Inc. Collaborates with NIAID to Evaluate Chrysalin® for Treatment of Cutaneous Radiation Injury
Contract Type
collaboration
GalvestonBiotechnologyHealthcareDescription
Chrysalis BioTherapeutics, Inc. has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for evaluating Chrysalin for the treatment of Cutaneous Radiation Injury (CRI). The collaboration aims to assess the potential of Chrysalin in reversing radiation-induced inflammation and dermal injury caused by RCI.